GLUE · Monte Rosa Therapeutics, Inc.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.18 to $23.23, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.83 to $23.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

25% of the shares underlying this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

The shares underlying this option are fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

New Enterprise Associates 17, L.P. ("NEA 17") made a pro rata distribution of 1,000,000 shares of Common Stock of the Issuer to its general partner and limited partners for no consideration on July 1, 2026.

The Reporting Person is a manager of NEA 17 GP, LLC ("NEA 17 GP"), which is the sole general partner of NEA Partners 17, L.P. ("NEA Partners 17"). NEA Partners 17 is the sole general partner of NEA 17, the direct beneficial owner of the securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

NEA Partners 17 made a distribution of 15,000 shares of Common Stock of the Issuer for no consideration on July 1, 2026.

The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest.

NEA Partners 17 received 15,000 shares of Common Stock of the Issuer in the distribution made by NEA 17 on July 1, 2026.

The Reporting Person is a manager of NEA 17 GP, the sole general partner of NEA Partners 17, the direct beneficial owner of the shares. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the securities held by NEA Partners 17 in which the Reporting Person has no pecuniary interest.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

The shares underlying this option are fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

Includes 620 shares acquired under the Issuer's 2021 Employee Stock Purchase Program on June 30, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

The shares underlying this option are fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

The shares underlying this option are fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.30 to $21.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

The shares underlying this option are fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

The shares underlying this option are fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 4, 2026.

The shares underlying this option are fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

This option is fully vested and exercisable.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

25% of this option vested on May 28, 2025, with the remainder vesting in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 19, 2026.

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 11, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service at such time.

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.69 to $19.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on May 14, 2025.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.69 to $19.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.74 to $20.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.

This option is fully vested and exercisable.